Most of the private credit conversation happening right now is about the estimate. This edition is about the obligation.
Something shifted in the market over the past several weeks. Capital structuring professionals, private credit managers, and family office allocators have been arriving at the same question from different directions: what does the architecture actually look like behind the headline? Not the story. Not the track record. The mechanism.
This edition answers that question properly.
The instrument question. Before evaluating a structure, the first question is what kind of instrument it actually is. A direct bilateral loan is not a fund, not a managed vehicle, not a pooled product. Applying a fund due diligence framework to a bilateral loan doesn't make you more careful. It makes you more confused. The checklist has to match the instrument.
The protection question. Principal protection is one of the most overused phrases in alternatives marketing. What it usually means is principal mitigation: a stop-loss, a guarantee from a counterparty, a structural feature that depends on market conditions to hold. Actual principal protection means an insurance policy in the investor's name, issued directly by a Tier 1 carrier, before a single dollar moves. The difference between those two things is the difference between a promise and a mechanism.
The beneficiary question. In many structured products, the chain between an investor and their protection is longer than it appears. A fund holds the policy. A trustee administers it. A manager interprets the trigger. The investor is several steps removed from the mechanism that was supposed to protect them. The question worth asking is not whether protection exists. It is whether the investor is the direct named beneficiary with a defined enforcement trigger. Those are not always the same answer.
The validation question. A Tier 1 insurer's willingness to underwrite principal protection tells you something that a three-year track record cannot: what a rigorous, commercially incentivized institution thinks about the risk right now. Insurers don't underwrite as a favour. They price risk for a living. Their participation means the structure passes internal standards that are in many ways more demanding than a standard institutional DD process because the insurer bears the consequence if they're wrong.
The correlation question. Non-correlation gets used as a selling point so often it has lost most of its meaning. A fixed contractual interest rate on a direct private loan doesn't move when equities reprice. It doesn't compress when credit spreads widen. It isn't ‘marked to market’ or NAV-dependent. That isn't non-correlation as a marketing claim. It's non-correlation as a structural fact - a consequence of the instrument's legal nature, not its investment strategy.
The right fit question. Not every allocator is the right fit for this kind of structure. If you need daily liquidity, this isn't it. If your mandate requires GIPS-compliant performance data, this won't satisfy it. But if you're managing a treasury sleeve that needs contractual fixed income, full principal protection, and zero correlation to public markets, and you're comfortable evaluating a structure on its legal and insurance mechanics rather than its historical returns, the conversation is worth having.
The allocators who fit tend to know within the first five minutes. The ones who don't tend to ask the same questions repeatedly and find the answers unsatisfying, not because the answers are wrong, but because the questions were built for a different instrument.
Knowing which camp you're in saves everyone time.
